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Purpose: Eyelid myoclonia with absences (EMA) is a generalized genetic epilepsy syndrome characterised by 
the hallmark of rapid blinking of the eyelids and an upward deviation of the eyeballs. Understanding the 
genetic architecture of EMA  is a challenging  task as eyelid myoclonia is also seen in other epilepsy 
syndromes.  
Method: The present study is based on a cohort of individuals with either only EMA, showing eyelid myoclonia 
with eye closure EEG bursts and/or photosensitivity (EMA), or with EMA associated with clinically evaluated 
intellectual disability or psychiatric conditions (EMA+).Whole-exome  sequencing (WES) was performed on 
probands and their parents, when available. WES data was analysed, trios were analysed for de novo and/or 
unique variants and the singletons for unique variants. Sanger sequencing was used to confirm variants.  
 
Results: We sequenced  112 individuals, including 19 trios, 40 singletons and 2 multiplex families. We 
identified 2 novel de novo CHD2 mutations in 2 EMA+ trios: a missense variant [c.4598 T>G] and a splice donor 
variant [c.3455+2 T>G]. We also identified a de novo frameshift deletion affecting KIAA2022 [c.2171del] in 
another EMA+ trio. All these variants were unique, with CADD score>20. Two singletons showed a previously 
reported mutation in the CHD2 gene: a frameshift variant [c.3734dupA] and a splice region variant 
[c.2577+7T>C]. The former variant was identified in an EMA+ case, and the latter in an EMA case. Overall, 
10.5% of trios showed a de novo CHD2 variant and 5% of singletons harboured mutation in this gene.  
Conclusion: CHD2 gene plays a key role in cerebral cortical development. Mutations in this genehave been 
reported for a broad spectrum of neurodevelopmental disorders, including EMA. KIAA2022 encodes a neurite 
extension and migration factor. Mutations in this gene have never been associated with EMA. Our study adds 
growing evidence implicating novel CHD2 and KIAA2022 mutations in EMA. 
 
